This multi-center, real-world study evaluated outcomes of tarlatamab in patients with small cell lung cancer (SCLC), examining efficacy and tolerability outside of controlled trial settings.
Real-world observational design limits causal inference; specific patient numbers, response rates, and survival data are not extractable from the abstract alone; potential selection bias across centers.
Real-world multi-center data on tarlatamab in SCLC may help clinicians contextualize trial results in broader patient populations, but full quantitative outcomes are needed before firm practice conclusions can be drawn.
Explore related topics
